CAPR today
$9.57-$0.67 (-6.49%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourLeaning Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minBullish
Daily trend turns up above $20.54
Key levels
Resistance$18.64
Resistance$10.72
Support$8.15
Support$5.67
Latest news & SEC filings
AnalystRoth Capital keeps Neutral rating on Capricor Therapeutics, lifts target to $10.5
AnalystCapricor Therapeutics gets Buy rating and $25 target from Jones Trading
EarningsCapricor reports wider-than-expected Q3 loss as stock rises
All CAPR news →About Capricor Therapeutics
Capricor Therapeutics creates therapies derived from cells and exosomes. Its lead candidate, Deramiocel, relies on cardiosphere-derived cells and targets Duchenne muscular dystrophy along with associated heart complications. The firm also pursues an exosome platform, including a SARS-CoV-2 vaccine candidate, alongside university and government health agency collaborators. It operates from the United States and has a distribution partner for the U.S. and Japanese markets.
Based on the company's 10-K filed Mar 17, 2026.
Nasdaq · Healthcare
CAPRICOR THERAPEUTICS, INC. (CAPR)
What Is the Price Target for CAPR?
SEPT Low Target
$10.50
SEPT Mid Target
$25.00
SEPT High Target
$28.00
Analyst Consensus
$25.00
Is CAPR a Buy or Sell Right Now?
Thesis
- •Revenue growing -11.6% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CAPR.
Start Free Trial →Is CAPR Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$21.03
25
Moat Score
NONE
3/9
Piotroski Score
5.0
Altman Z-Score
What Is Smart Money Doing with CAPR?
Insider Signal
SELLING
0 buys / 7 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Bergmann Anthony | officer | Buy | 3,000 | $4K | May 18, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →CAPR Growth Story
Revenue YoY
-11.6%
3yr Revenue CAGR
349.7%
EPS Growth YoY
-96.52%
FCF Growth YoY
-76.7%
Revenue Trend
STRONG
Dark Pool Trades for CAPR
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for CAPR, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:48:11 | $9.59 | 2,418 | $$23K | SELL |
| 20:45:31 | $9.57 | 1,250 | $$12K | SELL |
| 20:41:31 | $9.59 | 2,500 | $$24K | SELL |
| 20:39:16 | $9.59 | 3,640 | $$35K | MIDPOINT |
| 20:38:35 | $9.61 | 1,980 | $$19K | BUY |
5 dark pool trades shown · $$113K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for CAPR
PREVIEWSEPT Investing provides real-time options flow tracking for CAPR, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| PUT | $4 | Jan 15 | 63 | $$135 | 1 | SWEEP |
| PUT | $4 | Jan 15 | 63 | $$135 | 1 | SWEEP |
| PUT | $4 | Jan 15 | 63 | $$270 | 2 | SWEEP |
| CALL | $60 | Jan 15 | 63 | $$4950 | 110 | BLOCK |
| CALL | $60 | Jan 15 | 63 | $$2475 | 55 | SWEEP |
5 options trades shown · 40% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for CAPRICOR THERAPEUTICS, INC. (CAPR) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (5 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →CAPR — frequently asked questions
What is CAPR stock price today?
CAPRICOR THERAPEUTICS, INC. (CAPR) is at $9.57, down 6.49% (-$0.67) at the Nov 13, 2026 close.
Why is CAPR stock moving today?
Latest CAPR news — Nov 13, 2026: Roth Capital keeps Neutral rating on Capricor Therapeutics, lifts target to $10.5 · Nov 11, 2026: Capricor Therapeutics gets Buy rating and $25 target from Jones Trading
Why did CAPR stock move on Nov 11, 2026?
Capricor Therapeutics shares surged 16.27% to close at $11.22, well above the $9.65 open and near the day's high of $11.23, on heavy volume of over 9.6 million shares. The rally was driven by a bullish analyst initiation, as Jones Trading started coverage with a Buy rating and a $25 price target.
What is the CAPR price target?
The average analyst price target for CAPR is $25.00, ranging from $11 to $28, based on 6 analysts.
What do analysts rate CAPR?
Analyst ratings for CAPR: 5 Buy, 1 Hold, 3 Sell — consensus Buy.
Did CAPR beat earnings?
CAPR last reported on Nov 10, 2026: EPS -$0.73 vs -$0.44 expected — a miss of 66.4%.
Does CAPR pay a dividend?
CAPR does not currently pay a dividend.
What are CAPR support and resistance levels?
Support: $8.15, $5.67, $4.70. Resistance: $10.72, $18.64, $20.54.
What are insiders doing with CAPR?
Insider activity: SELLING, 0 buys and 7 sells in the last 90 days.
What is the latest news on CAPR?
Nov 13, 2026: Roth Capital keeps Neutral rating on Capricor Therapeutics, lifts target to $10.5 · Nov 11, 2026: Capricor Therapeutics gets Buy rating and $25 target from Jones Trading · Nov 11, 2026: Capricor reports wider-than-expected Q3 loss as stock rises